Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections

Pfizer

Status and phase: Completed; Phase 1

Conditions: Bacterial Infections

Treatments: Drug: Dalbavancin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00678106

A8841004

Details and patient eligibility

About

Adolescent subjects hospitalized for the treatment of bacterial infections will be given 1 gram of dalbavancin through their veins and levels of dalbavancin in blood and urine will be measured at different time points. Safety labs will also be checked on a regular basis to assess the safety of dalbavancin.

Enrollment: 10 patients

Sex: All

Ages: 12 to 17 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 12 to 17 year old adolescents hospitalized for the treatment of bacterial infections.

Exclusion criteria

• Patients being treated with vancomycin.
• Patients with liver and kidney failure.
• Pregnant female subjects.

Trial design

10 participants in 1 patient group

1

Experimental group

Treatment:

Drug: Dalbavancin